Abstract
We conducted a retrospective study to assess pharmacoeconomic outcomes of patients who received a daily dose of micafungin 100 mg or 150 mg to treat candidemia. The oncedaily 100-mg dose resulted in clinical and mycological outcomes similar to those achieved with 150 mg daily and succeeded in reducing drug-acquisition costs for treating hospitalized patients with candidemia.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 196-199 |
| Number of pages | 4 |
| Journal | P and T |
| Volume | 34 |
| Issue number | 4 |
| State | Published - Apr 2009 |
Keywords
- Candidemia
- Micafungin
- Pharmacoeconomics
ASJC Scopus subject areas
- Pharmacology (medical)